Agree. It's natural for investors to treat it as a success/failure decision when they are focused on the short-term. I just hope the FDA uses some common sense and treats this case similarly - there is a significant unmet need that very quickly needs to be addressed. And we have the drug that actually works - clear cut Phase 2 data. Don't delay us unnecessarily
IXC Price at posting:
64.5¢ Sentiment: Buy Disclosure: Held
